The Journal of Clinical Psychiatry

Supplementary Material

Article Title: Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting

- Authors: Mia C. Santucci, BA; Mina Ansari, MD/MPH; Sina Nikayin, MD; Rajiv Radhakrishnan, MBBS, MD; Taeho Greg Rhee, PhD; and Samuel T. Wilkinson, MD
- DOI Number: 10.4088/JCP.24m15376

LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE

- 1. <u>Table 1</u> Concomitant Medications During Acute Course
- 2. <u>Table 2</u> Medical and Psychiatric Comorbidities

DISCLAIMER

This Supplementary Material has been provided by the authors as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Develotronia Medication Class	
Psychotropic Medication Class	N (%)
Any Antidepressant (%)	23 (51.1)
SSRI	8 (17.8)
SNRI	7 (15.6)
TCA	3 (6.7)
MAOI	0
Other (Bupropion, mirtazapine)	11 (24.4)
Antipsychotic	25 (55.6)
Mood stabilizer/anticonvulsant	29 (64.4)
Valproic acid	5 (11.1)
Lamotrigine	19 (42.2)
Gabapentin	10 (22.2)
Other (Topiramate, Oxcarbezapine, carbamazepine)	5 (11.1)
Lithium	15 (33.3)
Sedative/hypnotic	22 (48.9)
Benzodiazepine	19 (42.2)
Zolpidem	3 (6.7)
Zaleplon	1 (2.2)
Stimulant	6 (13.3)
Any psychotropic	43 (95.6)
Other	27 (60.0)
Trazodone	11 (24.4)
Hydroxyzine	7 (15.6)
Buspirone	2 (4.4)
Other	11 (24.4)

Supplementary Table 1. Concomitant medications during acute course.

N (%)
1 (2.2)
4 (8.9)
4 (8.9)
4 (8.9)
1 (2.2)
5 (11.1)
9 (20.0)
9 (20.0)
5 (11.1)
2 (4.4)
5 (11.1)
3 (6.7)
21 (46.7)
3 (6.7)
10 (22.2)
1 (2.2)
3 (6.7)
3 (6.7)
4 (8.9)
2 (4.4)
3 (6.7)

Supplementary Table 2. Medical and Psychiatric Comorbidities